HOKKAIDO UNIVERSITY
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- Private
- Established
- 1876-01-01
- Employees
- 501
- Market Cap
- -
- Website
- http://www.hokudai.ac.jp
Clinical Trials
173
Active:0
Completed:108
Trial Phases
4 Phases
Phase 1:1
Phase 2:2
Phase 4:1
+1 more phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (171 trials with phase data)• Click on a phase to view related trials
Not Applicable
167 (97.7%)Phase 2
2 (1.2%)Phase 1
1 (0.6%)Phase 4
1 (0.6%)No trials found
News
Gut Microbiome Metabolite HYA Shows Promise for Blood Sugar Management in Type 1 Diabetes
A novel study reveals that HYA, a gut microbiome-derived metabolite, effectively reduces post-meal blood sugar spikes in type 1 diabetes model rats through multiple mechanisms.
Ensitrelvir Shows 67% Reduction in COVID-19 Risk as First Effective Post-Exposure Prophylaxis in Phase 3 Trial
Shionogi's SCORPIO-PEP Phase 3 trial demonstrated ensitrelvir reduces COVID-19 risk by 67% in exposed household contacts, making it the first oral antiviral to successfully prevent COVID-19 after exposure.